Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
THYROCARE
Mr. Rahul Franklin Guha · Navi Mumbai, India · 1,906 employees
₹580.00
▲+0.05%THYROCARE (THYROCARE.NS) is poised for growth as the Indian diagnostics market expands, underpinned by rising demand for quality healthcare and the company's increasing scale and profitability.
Exchange
NSI
Currency
INR
Day range
₹574.00 – ₹584.55
52-week range
₹342.55 – ₹617.45
Sector
Healthcare
Industry
Diagnostics & Research
AI investment rating
AI analysis80% confidence
Current price of INR 580 appears reasonable given its P/E multiple of 52.68, but we view the stock as trading at a premium to its 1-year low, indicating potential upside in the longer term.
6.1% below the 1-year high · trend down
Hedge-fund memo
Today
The stock has traded sideways today, but remains within its established day range.
This week
The stock has gained 0.05% over the week, driven by the analyst consensus of a strong buy.
This month
Year-to-date, the stock has appreciated by 12.15%, driven largely by the expansion of the Indian diagnostics market.
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Bullish
24 headlines · 11 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 1 of 3 recent quarters (EPS actual vs. consensus).
3.22 vs 5.725
-43.76% surprise
2.98 vs 5.4
-44.81% surprise
2.1146 vs 1.9
11.29% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| THYROCARE | 92.31B | 52.68 | — | 26.99% | 24.30% |
| LALPATHLAB | 314.34B | 58.26 | — | 25.46% | 19.10% |
| METROPOLIS | 122.68B | 64.37 |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Increased competition in diagnostics services
Mitigation: THYROCARE has a strong brand and operational network, which will help mitigate competition risks
Regulatory risks related to diagnostic services
Mitigation: THYROCARE has been operational in the market for many years and has strong relationships with regulatory bodies
Business intelligence
Competitive moat
THYROCARE's extensive network of labs, strong brand, and operational efficiency provide a durable competitive advantage in the Indian diagnostics market.
Supply chain
—
M&A / strategic moves
No notable recent activity flagged.
Catalyst calendar
Q2FY24 revenue growth
Expansion into new geographies
Thesis builder
Bull case
THYROCARE will continue to expand its market share driven by its strong brand, operational efficiency, and the growing demand for diagnostics services in India.
Base case
THYROCARE will maintain its market position, driven by its large-scale operations and profitability.
Bear case
THYROCARE will face increased competition and operational disruptions, impacting its profitability and market share.
Time horizon
2027-2029
Est. CAGR
12-15%
Entry (qual.)
Investors can consider THYROCARE for a medium-term perspective, as the company is poised for growth driven by expanding market demand.
Exit (qual.)
Investors may consider selling THYROCARE if the diagnostics market demand slows down significantly, or if the company faces unforeseen operational disruptions.
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how THYROCARE fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain THYROCARE for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
—
Investors with a medium to long-term perspective may consider THYROCARE for its growth potential.
scanx.trade·1d ago·PAT rises 34% to ₹51.33 crore
healthcareexecutive.in·2d ago·revenue of INR 240.02 Cr in Q1FY27
Business Today·2d ago·Bullish on shares
Whalesbook·2d ago·Strong Q1 FY27 Results
Whalesbook·2d ago·24.3% YoY growth in revenue
Whalesbook·2d ago·24.3% growth and ₹51.3 crore profit
Whalesbook·2d ago·Zabardast growth in Q1 FY27 earnings
MarketsMojo·2d ago·Surges 7.14% to Day's High
MarketsMojo·2d ago·52-Week High of Rs 600.5
MarketsMojo·2d ago·All-Time High of Rs 600.5
scanx.trade·3d ago·34% net profit surge in FY26
simplywall.st·3d ago·Just Missed Earnings
scanx.trade·4d ago·Evaluates demerger
TradingView·4d ago·Revenue Breakdown
Whalesbook·4d ago·Demerger and Q1 results better than expectations
Whalesbook·4d ago·Demerger plan, Q1 results better
Whalesbook·5d ago·Strong YoY growth in Q1 FY27 Results
Whalesbook·5d ago·Strong Q1 FY27 Results announcement
Whalesbook·5d ago·Strong growth in Q1 FY27 Results
Entrepreneur India·5d ago·34% jump in Q1FY27 Earnings
Moneycontrol.com·5d ago·Rating by ICICI Securities
Business Standard·5d ago·34% YoY rise in PAT, jumps
scanx.trade·5d ago·Q4FY27 earnings call recording
BW Disrupt·6d ago·34% rise in Q1 Profit, revenue climbs
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
| 13.37% |
| 16.51% |
| 23.00% |
| NH | 420.54B | 52.03 | 19.84% | 13.72% | 75.80% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹574.00
Resistance (day/52w high)
₹584.55
Volume
3,80,550
Trend
down
RSI (14)
62
MACD
bullish
MA cross
golden
50-day MA
₹530.88
200-day MA
₹453.39
vs 200-DMA
27.9%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.
Overall conviction 80%